



1FW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/732,901

Filing Date

December 9, 2003

First Named Inventor

Robert J. Fletterick

Group Art Unit

1641

Examiner Name

Unassigned

Total Number of Pages in This Submission

Attorney Docket Number

407J-000610US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Response
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
 - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):

PTO-1449 form, Cited References and receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Angela P. Horne, Ph.D., Reg. No. 41,079, Quine Intellectual Property Law Group, P.C.

Signature

Angela P. Horne, PhD

Date

July 7, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name


Evelyn Gomez

Signature

Evelyn Gomez

Date


July 7, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on July 7, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By


Evelyn Gomez

Attorney Docket No. 407J-000610US
Client Ref. No. 2003-236-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert J. Fletterick, et al.

Examiner: Unassigned

Application No.: 10/732,901

Art Unit: 1641

Filed: December 9, 2003

For: A METHOD FOR CREATING
NUCLEAR RECEPTOR ACTIVITY
MODULATING
PHARMACEUTICALS

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Robert J. Fletterick, et al.
Application No.: 10/732,901
Page 2


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Angela P. Horne, Ph.D.
Reg. No. 41,079

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/732,901
Filing Date	December 9, 2003
First Named Inventor	Robert J. Fletterick
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	407J-000610US
Date Submitted	July 7, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,883,294		Scanlan et al.	03-16-1999	
	2	6,236,946		Scanlan et al.	05-22-2001	
	3	6,266,622		Scanlan et al.	07-24-2001	
	4	2004/0110154		Baxter et al.	06-10-2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	5	PCT	03/39257		The Regents of the University of California			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	6	BARRY et al., "Interactions of SKIP/NCoA-62, TFIIB and Retinoid X Receptor with Vitamin D Receptor Helix H10 Residues" <u>J. Biol. Chem.</u> (2003) Vol. 278: 8224-8228.	
	7	BOURGUET et al., "Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor RXR- α " <u>Nature</u> (1995) Vol. 375:377-382.	
	8	BRZOWSKI et al., "Molecular Basis of Agonism in the Oestrogen Receptor" <u>Nature</u> (1997) Vol. 389:753-758.	
	9	CHANG et al., "A Thyroid Hormone Receptor Coactivator Negatively Regulated by the Retinoblastoma Protein" <u>Proc. Natl. Acad. Sci. USA</u> (1997) Vol. 94: 9040-9045.	
	10	CHANG et al., "Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β " <u>Mol Cell Biol</u> (1999) Vol. 19:8226-8239.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/732,901
	Filing Date	December 9, 2003
	First Named Inventor	Robert J. Fletterick
	Group Art Unit	1641
	Examiner Name	Unassigned
	Attorney Docket Number	407J-000610US
	Date Submitted	July 7, 2004

11	DARIMONT et al., "Structure and Specificity of Nuclear Receptor-Coactivator Interactions." <u>Genes Dev.</u> (1998) Vol. 12:3343-3356.
12	FENG et al., "Hormone-Dependent Coactivator Binding to a Hydrophobic Cleft on Nuclear Receptors" <u>Science</u> (1998) Vol. 280:1747-1749.
13	FONDELL et al., "Ligand Induction of a Transcriptionally Active Thyroid Hormone Receptor Coativator Complex" <u>Proc. Natl. Acad. Sci. USA</u> (1996) Vol.93: 8329-8333.
14	GEISTLINGER and GUY "An inhibitor of the interaction of thyroid hormone receptor β and glucocorticoid interacting protein 1" <u>J. Am. Chem. Soc.</u> (2001) Vol. 123:1525-1526.
15	HEERY et al., "A Signature Motif in Transcriptional Co-activators Mediates Binding to Nuclear Receptors" <u>Nature</u> (1997) Vol. 387:733-736.
16	KAKIZAWA et al., "Ligand-dependent Heterodimerization of Thyroid Hormone Receptor and Retinoid X Receptor" <u>J. Biol. Chem.</u> (1997) Vol. 272(38): 23799-23804.
17	LIN et al., "A Conformational Switch in Nuclear Hormone Receptors Is Involved in Coupling Hormone Binding to Corepressor Release" <u>Mol. Cell Biol.</u> (1997) Vol. 17:6131-6138.
18	MARIMUTHU et al., "TR Surfaces and Conformations Required to Bind Nuclear Receptor Corepressor" <u>Mol Endocrinol</u> (2002) Vol. 16:271-286.
19	NORRIS et al., "Peptide Antagonists of the Human Estrogen Receptor" <u>Science</u> (1999) Vol. 285:744-746.
20	ONATE et. al., "Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily" <u>Science</u> (1995) Vol. 270:1354-1357.
21	RENAUD et al., "Crystal Structure of the RAR- γ Ligand-Binding Domain Bound to all- <i>trans</i> Retinoic Acid" <u>Nature</u> (1995) Vol. 378: 681-689.
22	SACK et al., "Crystallographic Structures of the Ligand-binding Domains of the Androgen Receptor and its T877A Mutant Complexed with the Natural Agonist Dihydrotestosterone" <u>Proc. Natl. Acad. Sci. USA.</u> (2001) Vol. 98: 4904-4909.
23	SEIELSTAD et al., "Molecular Characterization by Mass Spectrometry of the Human Estrogen Receptor Ligand-Binding Domain Expressed in <i>Escherichia Coli</i> " <u>Molecular Endocrinology</u> , (1995) Vol. 9:647-658.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/732,901
	Filing Date	December 9, 2003
	First Named Inventor	Robert J. Fletterick
	Group Art Unit	1641
	Examiner Name	Unassigned
	Attorney Docket Number	407J-000610US
	Date Submitted	July 7, 2004

24	SHIBATA et al., "Role of Co-activators and Co-repressors in the Mechanism of Steroid/Thyroid Receptor Action" <u>Recent Prog. Horm. Res.</u> (1997) Vol. 52: 141-164.	
25	TAGAMI et al., "Nuclear Receptor Corepressors Activate Rather than Suppress Basal Transcription of Genes That are Negatively Regulated by Thyroid Hormone" <u>Mol. and Cell. Biol.</u> (1997) Vol. 17(5): 2642-2648.	
26	WAGNER et al., "A Structural Role for Hormone in the Thyroid Hormone Receptor" <u>Nature</u> (1995) Vol. 378: 690-697.	
27	WIJAYARATNE et al., "Comparative Analyses of Mechanistic Differences Among Antiestrogens" <u>Endocrinology</u> . (1999) Vol. 140(12):5828-5840.	
28	YEN, "Physiological and Molecular Basis of Thyroid Hormone Action" <u>Physiological Reviews</u> (2001) Vol.81(3):1097-1142.	
29	ZHU et al. "The Differential Hormone-dependent Transcriptional Activation of Thyroid Hormone Receptor Isoforms Is Medicated by Interplay of Their Domains" <u>J. Biol. Chem.</u> (1997) Vol. 272(14): 9048-9054.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.